(Reuters) – COVID-19 vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said on Thursday. The news comes as Moderna Inc (MRNA.O), which is at the forefront of the country’s vaccine development efforts, reiterated earlier in […]

Only a few weeks after announcing receipt of a green light from the U.S. Food and Drug Administration to begin a 30,000-patient Phase III clinical trial of a COVID-19 vaccine, Moderna indicated the start date was pushed back.

More than three dozen U.S. states saw a rise in COVID-19 cases, according to a Reuters tally on Thursday and the nation set a new record with more than 51,000 infections in a single day as a fresh wave of the pandemic spread across the nation.

The U.S. Food and Drug Administration approved GlaxoSmithKline Plc’s HIV drug Rukobia to treat adult patients who have run out of treatment options.

Regeneron Pharmaceuticals and Sanofi said their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing the medicine in the most critically ill COVID-19 patients.

South San Francisco-based Annexon, focused on drugs for autoimmune and neurodegenerative disorders, closed on a $100 million Series C financing led by Redmile Group.